OSTEOPORE LIMITED — Investor Presentation 2021

Nov 21, 2021

Empowering Natural Tissue Regeneration

INVESTOR PRESENTATION N O V E M B E R 2 0 2 1

==> picture [32 x 32] intentionally omitted <==

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M

DISCLAIMER

This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection wit h any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connec tion with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Inve stments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company . Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the S ecurities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

==> picture [32 x 32] intentionally omitted <==

2

O S T E O P O R E . C O M

I N V E S T O R P R E S E N T A T I O N

NOVEL IMPLANTS THAT FACILITATE BONE & TISSUE REGENERATION

Breakthrough Technology

==> picture [337 x 197] intentionally omitted <==

----- Start of picture text -----

World first biomimetic implants
developed in collaboration with
leading research institutions and
supported by granted patents.
Su erior Products
p
----- End of picture text -----

Superior, commercially ready products for off-the-shelf use by surgeons conducting high volume routine procedures. Craniofacial Re ulator Clearance g y

==> picture [135 x 60] intentionally omitted <==

==> picture [180 x 107] intentionally omitted <==

Value Creating

A clear focus on developing revenue streams to deliver high margin growth underlies the drive toward sustainable value creation.

==> picture [216 x 216] intentionally omitted <==

+US$100Bn Markets

Global expansion underway and distribution partners secured in most major markets to penetrate the US$3.9bn bone graft and US$100bn permanent implant sectors.

Near-term Growth Catalysts

Significant opportunity to regain revenue momentum as the effects of COVID-19 diminish.

==> picture [32 x 32] intentionally omitted <==

O S T E O P O R E . C O M 3

I N V E S T O R P R E S E N T A T I O N

ASX REGENERATIVE MEDTECH LANDSCAPE

Regenerative medicine treats injuries and diseases by harnessing the body’s own regenerative capabilities to regrow, repair or replace damaged or diseased cells, organs or tissues.

Treatments include the generation and use of therapeutic stem cells, tissue regeneration and the production of select artificial organs.

Osteopore is focused on the bone, cartilage and tendon sectors and is the only company using biomimetic scaffolds that dissolve over time leaving only healthy bone and tissue.

==> picture [915 x 648] intentionally omitted <==

----- Start of picture text -----

Avita
(ASX: AVH)
$565.80m
BONE
Osteopore
(ASX: OSX)
$28.14m
Mesoblast
(ASX: MSB)
$1.06bn
----- End of picture text -----

==> picture [111 x 305] intentionally omitted <==

----- Start of picture text -----

Polynovo
(ASX: PNV)
$988.77m
Cynata
(ASX: CYP)
$81.66m
Orthocell
(ASX: OCC)
$96.05m
----- End of picture text -----

==> picture [505 x 490] intentionally omitted <==

----- Start of picture text -----

$988.77m
Cynata
(ASX: CYP)
$81.66m
Orthocell
(ASX: OCC)
$96.05m
Aroa
(ASX: ARX)
$381.17m
Market capitalisation as at 11/11/2021
Indicative business focus based on publicly available information
----- End of picture text -----

O S T E O P O R E . C O M 4

I N V E S T O R P R E S E N T A T I O N

==> picture [500 x 431] intentionally omitted <==

----- Start of picture text -----

GROUND-BREAKING
UNIVERSITY RESEARCH
----- End of picture text -----

==> picture [502 x 355] intentionally omitted <==

----- Start of picture text -----

HOSPITALS AND
HEALTHCARE INSTITUTES
----- End of picture text -----

STRONG FOCUS ON COLLABORATIVE PARTNERSHIPS

Product development partnerships Cross-promotion sales agreements Combining complementary technology

SCIENCE AND INDUSTRY PARTNERS

==> picture [538 x 178] intentionally omitted <==

----- Start of picture text -----

LEADERS IN LIFE SCIENCES
----- End of picture text -----

==> picture [538 x 196] intentionally omitted <==

----- Start of picture text -----

CAD & AI
----- End of picture text -----

MANUFACTURING TECHNOLOGY

==> picture [32 x 32] intentionally omitted <==

O S T E O P O R E . C O M 5

I N V E S T O R P R E S E N T A T I O N

FOUNDATIONAL PLATFORM TO EMPOWER TISSUE REGENERATION

==> picture [397 x 25] intentionally omitted <==

----- Start of picture text -----

Novel process to regenerate bone
----- End of picture text -----

==> picture [680 x 449] intentionally omitted <==

----- Start of picture text -----

IMPLANT DRAWS
IN BLOOD
1
Biomimetic microstructures allow
blood to be drawn into the implant
before inserting into the body.
BONE GROWS
ON SCAFFOLDS
Once in the body the scaffold
2
attracts cells and blood vessels,
facilitating bone growth in-
between the microstructures.
----- End of picture text -----

==> picture [304 x 66] intentionally omitted <==

----- Start of picture text -----

Biomimetic microstructures allow
blood to be drawn into the implant
before inserting into the body.
----- End of picture text -----

==> picture [515 x 165] intentionally omitted <==

----- Start of picture text -----

IMPLANT
DISSOLVES
3
----- End of picture text -----

==> picture [361 x 66] intentionally omitted <==

----- Start of picture text -----

The implants naturally and predictably
dissolve over a period of 18-24 months to
leave only natural healthy bone.
----- End of picture text -----

==> picture [217 x 217] intentionally omitted <==

Proven applications across the entire body

CRANIOFACIAL & ORAL MAXILLOFACIAL Multiple products that support craniofacial surgeries for regenerating bone within the head, skull, face and jaw.

AESTHETIC

Applications for aesthetic surgery procedures that improve the appearance of the face and body.

DENTAL - OMF

Applications that promote vertical bone growth in the jaw following tooth removal.

ORTHOPAEDIC*

A range of orthopaedic applications, where significant lengths of long bones need to be regenerated.

*Promising outcomes in early clinical evaluation based on pipeline technology

==> picture [32 x 32] intentionally omitted <==

O S T E O P O R E . C O M 6

I N V E S T O R P R E S E N T A T I O N

• COMPETIVITE STRENGTHS LEVERAGED BY SOLVING UNMET CLINICAL NEEDS

==> picture [1694 x 799] intentionally omitted <==

----- Start of picture text -----

TRADITIONAL PROCEDURES
BONE GRAFT
US$3.9bn
Potential for infection and
lasting pain at harvest site Bone Graft Substitutes Proven to be Unlikely
Highly customisable
Market by 2025 to biomimic different effective in ~50k inflammation
Potential for body to
procedures or infection
bone types
completely absorb the graft
with no bone regeneration
Leaves only
Naturally dissolves Extremely low post
healthy bone
over a predictable surgery complication
PERMANENT IMPLANTS
tissue
time frame rates to date
Non-biodegradable with a
high potential for post
US$100bn
Bone Graft 6 – 19% [1,2,3]
surgical complications
Permanent Implant
Sales REPORTED COMPLICATION RATES
Difficult to micro-adjust
for a better fit during the
surgical procedure
25 – 33% [4,5,6]
Permanent Implants
Osteopore PSI REPORTED COMPLICATION RATES
0.01%
Sources 1-6 located in in Appendix slide 17
O S T E O P O R E . C O M 7
----- End of picture text -----

==> picture [983 x 776] intentionally omitted <==

----- Start of picture text -----

TRADITIONAL PROCEDURES
BONE GRAFT
US$3.9bn
Potential for infection and
Bone Graft Substitutes
lasting pain at harvest site
Market by 2025
Potential for body to
completely absorb the graft
with no bone regeneration
PERMANENT IMPLANTS
Non-biodegradable with a
high potential for post
US$100bn
surgical complications
Permanent Implant
Sales
Difficult to micro-adjust
for a better fit during the
surgical procedure
Osteopore PSI
----- End of picture text -----

I N V E S T O R P R E S E N T A T I O N

Source for market size data: Allied Market Research, BCC Research

Osteopore’s current market penetration is evident in its annual revenue figures announced on 26 Feb 2021 and in subsequent financial repo rting. Osteopore cautions investors that there are regulatory barriers and unique access challenges associated with entry into new m arkets, which may adversely impact entities’ ability to access such markets.

==> picture [32 x 32] intentionally omitted <==

• STRONG PRODUCT PIPELINE WITH SIGNIFICANT ADDRESSABLE MARKETS

==> picture [188 x 13] intentionally omitted <==

----- Start of picture text -----

SURGICAL SUBSPECIALTY
----- End of picture text -----

==> picture [14 x 289] intentionally omitted <==

----- Start of picture text -----

EXISTING COMMERCIAL PRODUCTS
----- End of picture text -----

==> picture [246 x 274] intentionally omitted <==

----- Start of picture text -----

CRANIOFACIAL
DENTAL
----- End of picture text -----

==> picture [291 x 361] intentionally omitted <==

----- Start of picture text -----

ORAL
MAXILLOFACIAL
ORTHOPAEDIC
AESTHETIC
PIPELINE
----- End of picture text -----

==> picture [215 x 30] intentionally omitted <==

----- Start of picture text -----

PRODUCTS FOR INDIVIDUAL
APPLICATIONS
----- End of picture text -----

REGULATORY CLEARANCE FY20 FY21 FY22 FY23 FY24 FY25 MARKET OPPORTUNITY SALES AVENUE APPLICATIONS Burr Hole Procedure Neurological Shunt Procedure Craniotomy Cranioplasty DIRECT & Craniosynostosis ~USD 1.0 bn[1] DISTRIBUTION Endoscopic Skull Base Surgery PARTNERS Orbital Floor Reconstruction Septoplasty Multiple SEA territories Patient Specific Implants • Singapore & Multiple SEA Socket Preservation • To initiate clinical validation Initial Singapore & SEA Sales DIRECT Guided Bone Regeneration to support wider adoption Immediate Implant Loading • (SINGAPORE ONLY) To initiate clinical trials for Guide Tissue Regeneration EU access ~USD 1.67 bn in 2028 Cleft Palate reconstruction 8.46% CAGR[2] • Undergoing trials to gain SPECIAL ACCESS Mandible reconstruction regulatory indication for use SALES Buccal Defect reconstruction • Tibia reconstruction Special access product whereby High Tibia Osteotomy surgeon requests its use SPECIAL ACCESS • Clavicle reconstruction To initiate clinical trials USD 2.0 bn[1] SALES • Tendon repair Preparing 510k submission by Radial reconstruction Q1 2022 Genioplasty (chin) • To initiate trials to gain SPECIAL ACCESS Nipple reconstruction USD 1.0 bn[3] regulatory indication for use SALES Breast reconstruction

(1) Cetas Healthcare 2020

(2) Verified Market Research 2021: Dental Membrane And Bone Graft Substitutes Market Size And Forecast (3) Based on the 2019 annual survey statistics provided by the International Society of Aesthetic Plastic Surgery

==> picture [32 x 32] intentionally omitted <==

O S T E O P O R E . C O M 8

I N V E S T O R P R E S E N T A T I O N

Product Clinical Regulatory Commercial Development Trials Approvals Sales

ANTICIPATED REGULATORY MILESTONES China ▪ [expected] Guangdong-Hong Kong-Macau Greater Bay Area market access for craniofacial products ▪ Initiate market entry process for NMPA for craniofacial products Australia ▪ Authorised Prescriber market access in Australia for rhinoplasty application USA ▪ Lodge US 510(k) submission for orthopaedic application Korea ▪ Lodge MFDS application for orthopaedic application with new generation material Pakistan ▪ [expected] DRAP approval for craniofacial products Switzerland ▪ [expected] Swissmedic approval for craniofacial products Europe ▪ Lodge EU application for Custom Made Device with new generation material ▪ Launch clinical trials for cranioplasty application with new generation material Australia ▪ Authorised Prescriber market access in Australia for orthopaedic application Colombia ▪ [expected] INVIMA approval for craniofacial products UK ▪ Lodge UKCA application for craniofacial products Singapore ▪ Lodge HSA submission for Patient Matched Device with new generation material China ▪ Initiate market entry process for NMPA (clinical trial) with craniofacial products Europe ▪ [expected] EU approval for Custom Made Device with new generation material ▪ Lodge EU application for Custom Made Device, Long Bone Reconstruction with new generation material Australia ▪ Lodge TGA submission for cranioplasty Patient Matched Device with new generation material Singapore • Lodge HSA submission for orthopaedic application with new generation material USA ▪ [expected] US 510(k) clearance for orthopaedic application with new generation material Korea ▪ [expected] MFDS approval for orthopaedic application with new generation material China ▪ [expected] NMPA approval for craniofacial products Europe ▪ Lodge CE mark application for Patient Matched Devices with new generation material ▪ [expected] EU approval for Custom Made Device, Long Bone Reconstruction with new generation material Australia ▪ [expected] TGA approval for Patient Matched Device with new generation material Q1 - Q2 CY22 Q3 – Q4 CY22 CY23 – CY24 Abbreviations NMPA National Medical Products Administration, China DRAP Drug Regulatory Authority of Pakistan INVIVMA Instituto Nacioinal de Vigilancia de Medicamentos y Alimentos HSA Health Sciences Authority UKCA UK Competent Authority MFDS Ministry of Food and Drug Safety

==> picture [32 x 32] intentionally omitted <==

O S T E O P O R E . C O M 9

I N V E S T O R P R E S E N T A T I O N

POST-COVID GROWTH STRATEGY Horizon 1: Next 12 to 18 months Horizon 2: Next 18 to 36 months Horizon 3: >36 months Grow revenue across current Launch additional products Develop and commercialise commercial product line for new areas of treatment breakthrough technology Strategy Strategy Strategy Investigating the viability of new materials and Build upon existing regulatory clearances to develop Secure regulatory clearance in existing key markets biologics to accelerate bone and tissue growth and strengthen brand recognition and uptake in for new geometric shapes suitable for applications and developing new implants to potentially assist core bone regeneration applications. in new areas of regenerative bone treatment. in growing cartilage and other tissue types. Drivers Drivers Drivers • Proven ability to successfully develop and launch • • World class development partners. Global regulatory approval. products globally. • • Highly credentialed research and Fully trained sales team. • New products under development use the same clinical advisor teams. regulatory approved materials and technology. • Building revenue in established and new markets • Unprecedented access to surgeon’s through relationships with specialist • Previous clinical data from commercial products and hospitals with innovative, early distributorships with existing links to craniofacial allows for accelerated development timeframes. adoption protocols for clinical trials. surgeons. EXISTING OSTEOPORE TECHNOLOGY NEW TECHNOLOGY

==> picture [32 x 32] intentionally omitted <==

O S T E O P O R E . C O M 1 0

I N V E S T O R P R E S E N T A T I O N

ENCOURAGING TAILWINDS EXPECTED TO DRIVE PRODUCT UPTAKE

==> picture [519 x 342] intentionally omitted <==

----- Start of picture text -----

POST-COVID
Vaccination rates are
expected to improve as
we head into CY2022.
----- End of picture text -----

==> picture [523 x 342] intentionally omitted <==

----- Start of picture text -----

ON-GROUND OPPORTUNITIES
Medical trade shows are starting to
revert back to “in-person” which will
help Osteopore® engage with
healthcare decision makers.
----- End of picture text -----

==> picture [524 x 340] intentionally omitted <==

----- Start of picture text -----

PENT-UP DEMAND
Fully dedicated sales team ready to take
advantage of a significant backlog of
elective surgeries which have been
disrupted by the pandemic.
----- End of picture text -----

==> picture [523 x 342] intentionally omitted <==

----- Start of picture text -----

GLOBAL CUSTOMER
RELATIONSHIPS
Continue to exploit Osteopore’s online sales
and business development capability that
was developed during the pandemic.
----- End of picture text -----

==> picture [523 x 338] intentionally omitted <==

----- Start of picture text -----

INCREASED ACCESS
Increased access to hospitals
and surgeons as the pandemic
resides in key markets.
----- End of picture text -----

==> picture [32 x 32] intentionally omitted <==

1 1

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M

NEW APPLICATIONS DENTAL AESTHETIC ORTHOPAEDIC Application Early clinical investigation Market access status Market growth strategy Socket preservation Singapore Multiple ASEAN countries ▪ Leverage approval in Singapore to drive sales in ASEAN ▪ Sign-up KOL to conduct training (Q2 2022) ▪ Conduct multi-centre post-market study for further clinical validation (Q2 2022) Buccal alveolar wall defect Singapore Multiple ASEAN countries ▪ Leverage approval in Singapore to drive sales in ASEAN ▪ Sign-up KOL to conduct training (Q1 2022) ▪ Authorised Prescriber Scheme for Australia (Q2 2022) ▪ Initiate clinical trials for market access to Europe (Q1 2023) Buccal alveolar wall defect with Immediate Implant Loading Singapore Multiple ASEAN countries ▪ Leverage approval in Singapore to drive sales in ASEAN ▪ Sign-up KOL to conduct training (Q1 2022) ▪ Authorised Prescriber Scheme for Australia (Q2 2022) ▪ Initiate clinical trials for market access to Europe (Q1 2023) Application Early clinical investigation Market access status Next evolution Patient Specific Long Bone Reconstruction ▪ Completed First- in-human implantation ▪ Initiated Clinical Trial in Q3 2021 ▪ To lodge Custom Made Device submission in EU Q4 2022 ▪ Special access sales where permitted and upon surgeon prescription Orthopaedic bone filler (standard device) ▪ Initiated First-in- Man implantation in Q1 2021 ▪ To lodge US FDA 510k submission in Q1 2022 ▪ To lodge Korea MFDS submission in Q2 2022 ▪ To lodge Singapore HSA submission in Q3 2022 ▪ Market access activity ▪ Special access sales where permitted and upon surgeon prescription Application Early clinical investigation Next evolution Nipple reconstruction ▪ In progress ▪ Systematic clinical development Genioplasty ▪ Achieved early clinical success ▪ To conduct more clinical evaluation with KOLs ▪ Systematic clinical development ORAL MAXILLOFACIAL Application Early clinical investigation Next evolution Cleft palate reconstruction ▪ To initiate in Q2 2022 ▪ Systematic clinical development Graft containment for segmental defects ▪ Achieved early clinical success ▪ To conduct more clinical evaluation with KOLs ▪ Systematic clinical development Patient Specific Implant ▪ Achieved early clinical success ▪ To conduct clinical trial ▪ Special access sales where appropriate and upon surgeon prescription	NEW APPLICATIONS DENTAL AESTHETIC ORTHOPAEDIC Application Early clinical investigation Market access status Market growth strategy Socket preservation Singapore Multiple ASEAN countries ▪ Leverage approval in Singapore to drive sales in ASEAN ▪ Sign-up KOL to conduct training (Q2 2022) ▪ Conduct multi-centre post-market study for further clinical validation (Q2 2022) Buccal alveolar wall defect Singapore Multiple ASEAN countries ▪ Leverage approval in Singapore to drive sales in ASEAN ▪ Sign-up KOL to conduct training (Q1 2022) ▪ Authorised Prescriber Scheme for Australia (Q2 2022) ▪ Initiate clinical trials for market access to Europe (Q1 2023) Buccal alveolar wall defect with Immediate Implant Loading Singapore Multiple ASEAN countries ▪ Leverage approval in Singapore to drive sales in ASEAN ▪ Sign-up KOL to conduct training (Q1 2022) ▪ Authorised Prescriber Scheme for Australia (Q2 2022) ▪ Initiate clinical trials for market access to Europe (Q1 2023) Application Early clinical investigation Market access status Next evolution Patient Specific Long Bone Reconstruction ▪ Completed First- in-human implantation ▪ Initiated Clinical Trial in Q3 2021 ▪ To lodge Custom Made Device submission in EU Q4 2022 ▪ Special access sales where permitted and upon surgeon prescription Orthopaedic bone filler (standard device) ▪ Initiated First-in- Man implantation in Q1 2021 ▪ To lodge US FDA 510k submission in Q1 2022 ▪ To lodge Korea MFDS submission in Q2 2022 ▪ To lodge Singapore HSA submission in Q3 2022 ▪ Market access activity ▪ Special access sales where permitted and upon surgeon prescription Application Early clinical investigation Next evolution Nipple reconstruction ▪ In progress ▪ Systematic clinical development Genioplasty ▪ Achieved early clinical success ▪ To conduct more clinical evaluation with KOLs ▪ Systematic clinical development ORAL MAXILLOFACIAL Application Early clinical investigation Next evolution Cleft palate reconstruction ▪ To initiate in Q2 2022 ▪ Systematic clinical development Graft containment for segmental defects ▪ Achieved early clinical success ▪ To conduct more clinical evaluation with KOLs ▪ Systematic clinical development Patient Specific Implant ▪ Achieved early clinical success ▪ To conduct clinical trial ▪ Special access sales where appropriate and upon surgeon prescription
	Application Early clinical investigation Market access status Next evolution
	Patient Specific Long Bone Reconstruction ▪ Completed First- in-human implantation ▪ Initiated Clinical Trial in Q3 2021 ▪ To lodge Custom Made Device submission in EU Q4 2022 ▪ Special access sales where permitted and upon surgeon prescription
	Orthopaedic bone filler (standard device) ▪ Initiated First-in- Man implantation in Q1 2021 ▪ To lodge US FDA 510k submission in Q1 2022 ▪ To lodge Korea MFDS submission in Q2 2022 ▪ To lodge Singapore HSA submission in Q3 2022 ▪ Market access activity ▪ Special access sales where permitted and upon surgeon prescription
	ORAL MAXILLOFACIAL
	Application Early clinical investigation Next evolution
	Cleft palate reconstruction ▪ To initiate in Q2 2022 ▪ Systematic clinical development
	Graft containment for segmental defects ▪ Achieved early clinical success ▪ To conduct more clinical evaluation with KOLs ▪ Systematic clinical development
Application Early clinical investigation Next evolution
	Patient Specific Implant ▪ Achieved early clinical success ▪ To conduct clinical trial ▪ Special access sales where appropriate and upon surgeon prescription
Nipple reconstruction ▪ In progress ▪ Systematic clinical development
Genioplasty ▪ Achieved early clinical success ▪ To conduct more clinical evaluation with KOLs ▪ Systematic clinical development

==> picture [32 x 32] intentionally omitted <==

O S T E O P O R E . C O M 1 2

I N V E S T O R P R E S E N T A T I O N

NEW TECHNOLOGY

ACCELERATING BONE REGENERATION Osteopore is investigating the viability of incorporating compounds to produce novel polycaprolactone polymer composites which could be used to develop additional products for adjacent therapeutic and surgical areas Large-scale collaboration currently in late stages of research and development programs

REGENERATION OF OTHER TISSUE Osteopore has successfully completed animal trials for knee cartilage regeneration, and the Osteopore scaffold may also potentially be used to assist with the regeneration of other tissue types. Clinical evaluation underway of rotator cuff repair for improved shoulder ROM

==> picture [32 x 32] intentionally omitted <==

1 3

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M

FINANCIALS

REVENUE

• Despite the considerable disruption COVID19 has caused the healthcare eco-system, Osteopore® has continued generate consistent quarterly revenue.

• As global vaccinations increase and the pandemic eases, Osteopore® expects revenue to return to its post COVID levels with increased momentum.

MARGINS

• Osteopore® continues to work towards maintaining and improving its margins.

• A gross margin of 74.9% of sales revenue was

• achieved in Q3 CY21.

• Osteopore® believes that its cost effective and high margin manufacturing process will ultimately become a major contributor towards the Company achieving profitability as revenue scales.

==> picture [543 x 406] intentionally omitted <==

----- Start of picture text -----

Q1 Q2 Q3 Q4 Q1 Q2 Q3
CY20 CY20 CY20 CY20 CY21 CY21 CY21
----- End of picture text -----

CAPITAL STRUCTURE

Shares on Issue[A]

117.2m

Total Options on Issue[B]

13.4m A$34m A$28m

Market Cap @ $0.29c[C] EV @ $0.29[C] CASH BALANCE[D]

A$5.9m

CY21 Average Quarterly Net Operating Cash Used

(A$894)

A: Shares on Issue includes 16.0m placement shares.

B: 9.7m options with an exercise price of $0.25 and an expiry date of 30 June 2022, 0.4m options with an exercise price of $1.00 and an expiry date in December 2022, 3m options with exercise price of $1.20 and expiry August 2023. 0.375 options with an exercise price of $0.624 and expiry Nov 2025 Option incentives held by executive management, directors & advisors.

C: Market Close, 30 Sept 2021

D: Cash balance at 30 Sept 2021

==> picture [32 x 32] intentionally omitted <==

O S T E O P O R E . C O M 1 4

I N V E S T O R P R E S E N T A T I O N

KEY TAKEAWAYS

==> picture [521 x 296] intentionally omitted <==

----- Start of picture text -----

Regenerative medical device
company with proven, superior
products that empower tissue
regeneration.
----- End of picture text -----

==> picture [521 x 297] intentionally omitted <==

----- Start of picture text -----

Significant opportunity to regain
revenue momentum as the effects
of COVID-19 diminish.
----- End of picture text -----

==> picture [522 x 296] intentionally omitted <==

----- Start of picture text -----

Fully trained and dedicated
sales team expected to drive
growth in the near term.
----- End of picture text -----

==> picture [522 x 300] intentionally omitted <==

----- Start of picture text -----

Systematic revenue growth
strategy aimed at delivering and
expanding revenue over three
time horizons.
----- End of picture text -----

==> picture [521 x 298] intentionally omitted <==

----- Start of picture text -----

Global expansion underway with
regulatory clearance and
distribution partners secured in
most major markets.
----- End of picture text -----

==> picture [521 x 296] intentionally omitted <==

----- Start of picture text -----

Complementary pipeline of
products being developed for
additional bone regeneration
applications.
----- End of picture text -----

==> picture [32 x 32] intentionally omitted <==

1 5

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M

==> picture [897 x 299] intentionally omitted <==

Carl Runde Chief Financial Officer M +61 400 118 017 E: carl_runde@osteopore.com

==> picture [32 x 32] intentionally omitted <==

1 6

I N V E S T O R P R E S E N T A T I O N

O S T E O P O R E . C O M

SOURCES

• 1 Dimitriou, R., Mataliotakis, G. I., Angoules, A. G., Kanakaris, N. K., & Giannoudis, P. V. (2011). Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. Injury, 42, S3-S15.

• 2 Younger, E. M., & Chapman, M. W. (1989). Morbidity at bone graft donor sites. Journal of orthopaedic trauma, 3(3), 192-195.

• 3 Arrington, E. D., Smith, W. J., Chambers, H. G., Bucknell, A. L., & Davino, N. A. (1996). Complications of iliac crest bone graft harvesting. Clinical Orthopaedics and Related Research®, 329, 300-309

• 4 Giese, H., Meyer, J., Unterberg, A., & Beynon, C. (2020). Long-term complications and implant survival rates after cranioplastic surgery: a single-center study of 392 patients. Neurosurgical Review, 1-9.

• 5 Wiggins, A., Austerberry, R., Morrison, D., Ho, K. M., & Honeybul, S. (2013). Cranioplasty with custom-made titanium plates—14 years experience. Neurosurgery, 72(2), 248-256.

• 6 Thien, A., King, N. K., Ang, B. T., Wang, E., & Ng, I. (2015). Comparison of polyetheretherketone and titanium cranioplasty after decompressive craniectomy. World neurosurgery, 83(2), 176-180.

• 7 cetas healthcare (2020). Market research conducted for Osteopore on the global cranial procedure market.

• 8 Sparks, D. S., Saifzadeh, S., Savi, F. M., Dlaska, C. E., Berner, A., Henkel, J., ... & Hutmacher, D. W. (2020). A preclinical large-animal model for the assessment of critical-size load-bearing bone defect reconstruction. Nature protocols, 15(3), 877-924.

• 9 Zhang, Z., & Teoh, S. H. (2014). Novel 3D polycaprolactone scaffold for ridge preservation – a pilot randomised controlled clinical trial. Clinical Oral Implants Research, 26, 271-277.

• 10 van Griensven, M., Biberthaler, P., & Rosado Balmayor, E. (2015). Clinical approaches to the healing of long bone defects. In Schantz, J-T. & Hutmacher, D.W. (2020), Advanced Therapies in Regenerative Medicine, Vol. 2, World Scientific, (pp. 217-231).

O S T E O P O R E . C O M 1 7

I N V E S T O R P R E S E N T A T I O N